Meropenem Ranbaxy (Uk) (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used to treat severe infections caused by susceptible bacteria.

• Complicated intra‑abdominal infections: provides bacterial clearance in severe abdominal sepsis.
• Complicated urinary tract infections: eradicates resistant uropathogens in hospital‑acquired UTIs.
• Nosocomial pneumonia: effective against ventilator‑associated and ICU‑acquired pneumonia.
• Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.
• Septicemia: rapidly reduces bacterial load in bloodstream infections.

• Meropenem binds to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability, cell lysis, and bacterial death. Its broad affinity for multiple PBPs confers activity against many Gram‑positive, Gram‑negative and anaerobic organisms.

Adverse reactions may occur with any intravenous antibiotic. Monitoring for side effects is recommended.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Headache: transient and usually resolves.
• Rash: erythematous skin eruption.
• Infusion site reactions: erythema or phlebitis at the injection site.
• Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile‑associated colitis: severe diarrhea with pseudomembranous colitis.
• Anaphylaxis: acute hypersensitivity reaction requiring emergency care.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Hepatic failure: rare but possible severe liver injury.

Use meropenem with caution in specific clinical situations and follow handling guidelines.

• Renal function: adjust dose in patients with impaired clearance.
• Allergy: avoid in individuals with known carbapenem or beta‑lactam hypersensitivity.
• Seizure risk: monitor closely in patients with a history of epilepsy or CNS disorders.
• Pregnancy: prescribe only when benefits outweigh potential risks.
• Drug interactions: review concomitant medications for possible interactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other agents, altering efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: meropenem reduces serum valproate levels, increasing seizure risk.
• Probenecid: may increase meropenem plasma concentrations, raising toxicity potential.

Moderate Interactions (Monitor Closely)

• Aminoglycosides (e.g., gentamicin): additive nephrotoxicity; monitor renal function.
• Loop diuretics: may enhance renal clearance of meropenem; adjust dose if needed.
• Anticoagulants (e.g., warfarin): occasional alteration of INR; check coagulation parameters.